Introduction
Age-related macular degeneration is the most common cause of severe vision loss in elderly persons in developed countries. Age related macular degeneration is a painless, irreversible, degenerative eye condition associated with the damage of photoreceptor cells (Figure1) [1] .
Two types of the disease are classified, dry and wet, the first being far more common, the latter usually worse and associated with metamorphosis and vision distortion, with loss of central vision. Various agents are used for treatment, and prevention of the disease, and dietary and life style considerations may avoid complications of the disease, keeping a stable visual acuity and quality of life. Early identification of the disease is of great importance.
The choroidal neovascularization is the primary lesion of age-related macular degeneration to be treated. The membrane extends anteriorly through defects in Bruch's membrane (Figure 2 ) into the space below the retinal pigment epithelium and/or neurosensory retina, leading to fluid accumulation, bleeding or lipids in the subretinal space. Fibrous tissue may appear, causing central vision loss. The current macular degeneration related to age treatment in its exudative form is the main challenge in the world of ophthalmology.
Because of recent research into biomaterials and nanotechnology [2] major advances has been gained in the field of intraocular injections and delivery systems. New therapies [3, 4] are recently presented to the patient in order to prevent neovascular age-related macular degeneration.
Several mechanisms have been proposed to explain these phenomena. Vascular endothelial growth factor (VEGF) [5] [6] [7] production when blocked lead to an increase in other angiogenic pathways as a compensatory mechanism, thus up-regulating VEGF production by macrophages within choroidal neovascular membranes [8, 9] .
Photodynamic therapy [10] is a modality is based on the fact that the choroidal neovascular membranes have tissue characteristics that differ from normal blood vessels in terms of retaining dye. The treatment, which uses a combination of drugs and laser therapy, a verteporfin photosensitive compound that localizes to the target tissue is injected into a peripheral vein and excited with laser light of a specific wavelength. Activated verteporfin forms free radicals, and coagulation of the leaking vessels responsible for cellular injury ensues.
Thermal laser photocoagulation was the treatment of choice for many years in the management of patients with wet ARMD. In this procedure, the laser is directed toward the choroidal neovascular membrane, to destroy it. This procedure, however, has been associated with a high rate of recurrence [11] .
Based on their histology, Gass classified CNVMs into Type 1 and Type 2. Type 1, the subepithelial CNV grows between the basement membrane of the RPE and the inner collagenous zone of Bruch's membrane [12] . The CNVs associated with punctate inner choroidopathy (PIC), presumed ocular histoplasmosis syndrome (POHS) and with other PSII are assumed to be Type 2 membranes; so called inflammatory membranes, and in Type 2, the CNV grows beneath the sensory retina, lying anteriorly to the RPE. Open Access
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Other modalities [13] [14] [15] [16] [17] of treatment include macular translocation, submacular surgery and photocoagulation of the feeder vessel, the last one, guided by green indocyanine, can result in a better outcome, with the focal treatment of the choroidal neovascular membrane complex.
Auto-antibodies against antiangiogenic agents have been documented in the systemic circulation of patients undergoing chronic anti-VEGF therapy for exudative age related macular degeneration, preventing the action of these agents. Choroidal neovascular lesion composition might well change with time with more mature and therefore less VEGF sensitive vessels, so that prompt us to overcome such difficulty with new agents available [18] .
The target layers of their retina and adjacent tissues, represented by the retinal pigment epithelium (RPE) and the Bruch membrane (BM) [19] , respectively, can be complicated by choroidal neovascular membrane, formed after damage to the retinal pigment epithelium. A protein, the pigment epithelium derived factor (PEDF), could have an inhibitory effect on ocular neovascularization, as well as the VEGF, an angiogenic factor [20] . The balance between these antiangiogenic and angiogenic [21] factors may halt or ensue the origin of the choroidal neovascular membrane. Activation of VEGF induces vascular permeability, endothelial cell proliferation, and cell migration thus resulting in the formation of a network of new vessels [22] . Several clinical trials test the relative efficacy of different drugs and subtypes of the choroidal neovascular membrane [23] [24] [25] .
Vascular endothelial growth factor (VEGF) has been implicated as a trigger process in the pathogenesis of ARMD-related choroidal neovascular membrane. Anti-VEGF agents for the treatment of choroidal neovascular membrane and are under active clinical investigation, and include anti-VEGF antibodies, gene therapy and protein kinase C inhibition and anti-VEGF aptamer. Many cases are shown to have resulted in a better outcome after intraocular injections with resolution of the membrane after most of times some intraocular injections ( Figure 3 ).
We show a case of subretinal neovascular membrane treated with bevacizumab that fails with recurrent neovascular membrane, and a new treatment switching the medication was indicated.
Case Report
We performed bevacizumab [2] intraocular injections in a patient with metamorphosia and CNV diagnosed on December, 2015. The patient was free of systemic symptoms, and had solely eye symptoms, manifested by metamorphosis in the left eye. The patient had visual acuity of counting fingers at 15 centimeters in the left eye, and 20/40 in the right eye. He had three injections of bevacizumab in December, 2015 followed by two more injections in January and February, 2016. He used to see a central blur out of the left eye and the right eye was asymptomatic. The patient was submitted to Oct -ocular computerized tomography and fluorescein angiography, before and after treatment. The patient was still counting fingers, but without the blur, and felt that his visual acuity got a lot better. The Oct pre-treatment showed a foveal minimum thickness of 313 microns and after the injections that increased to 340 microns, despite he noticed better visual acuity. The fluorescein angiography showed recurrent leakage from the membrane. Because of the risk of worsening both clinically and anatomically, and mainly because the lesion was still leaking and active, we decided to switch the drug to Ranibizumab, with the aim of halting the CNV formation quicker, to avoid worsening of the patient´s visual acuity (Figure 4 ).
Discussion
Antiangiogenic Compounds mostly used [26] [27] [28] :
Pegaptanib sodium
Pegaptanib [29] sodium is an aptamer against VEGF165, the isoform identified with pathological angiogenesis, the aptamer being an oligonucleotide that acts like a high affinity antibody to VEGF, neutralizing it before it can contact its receptor.
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Ranibizumab
Ranibizumab is a recombinant monoclonal antibody Fab fragment that neutralizes all active forms of VEGF-The FDA approved the use of ranibizumab for the treatment of all angiographic subtypes of subfoveal neovascular ARMD.
Bevacizumab [2] Bevacizumab is a humanized, recombinant monoclonal immunoglobulin G (IgG) antibody that binds and inhibits all VEGF isoforms and is currently approved for systemic use in metastatic colorectal cancer and non-small cell lung cancer, and is used for CNV secondary to ARMD since 2005. Most of the reports of bevacizumab are uncontrolled, open-label case series that have suggested functional and anatomical efficacy, short-term safety, and lower costs (Figures 5-9 ).
Aflibercept
The VIEW 1 and VIEW 2, two similarly designed double-masked, randomized multicenter clinical trials, demonstrated that intravitreal aflibercept dosed monthly or every 2 months after a loading dose of 3 monthly doses was non inferior to monthly ranibizumab.
The major concern for ocular complications following intravitreal anti-VEGF injections was for endophthalmitis, and non-infectious inflammation to the biologic anti-VEGF agents; other complications could be retinal tears, retinal detachment, tears of the retinal pigment epithelium; elevated intraocular pressure and cataracts.
Important designed studies
The Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) research group demonstrated that at 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively.
To date, there are several studies and many more coming on the way, demonstrating the efficacy of intravitreal injections [30] :
The MARINA (Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-related Macular Degeneration) study demonstrated the intravitreal administration of ranibizumab for two years to prevent vision loss while improving the mean visual acuity with low rates of serious adverse events, in patients with minimally classic or occult choroidal neovascularization secondary to age-related macular degeneration.
The ANCHOR ( anti-VEGF antibody for the treatment of predominantly classic choroidal neovascularization in age-related macular degeneration) study demonstrated that ranibizumab provided greater clinical benefit after two years than verteporfin PDT in patients with age related macular degeneration with new-onset, predominantly classic CNV.
The PRONTO (Prospective Optical coherence tomography imaging of patients with Neovascular age-related macular degeneration Treatment with intraocular ranibizumab) study used an Optical Coherence Tomography (OCT)-guided variable dosing regimen with intravitreal ranibizumab. During the first year, retreatment with ranibizumab was performed at each monthly visit if any criterion was fulfilled such as an increase in OCT-CFT of at least 100 μm or a loss of 5 letters or more. During the second year, the retreatment criteria were amended to include retreatment if any qualitative increase in the amount of fluid was detected using OCT. This study demonstrated that at month 24, the mean VA improved by 11.1 letters and the CFT decreased by 212 μm. The VA improved by 15 letters or more in 43% of patients. These VA and OCT outcomes were achieved with an average of 9.9 injections over 24 months. As-needed (PRN), OCT-guided variable dosing with intravitreal ranibizumab resulted in VA outcomes comparable to the outcomes from the phase III clinical studies (monthly injection), but fewer intravitreal injections were required.
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Pegaptanib appears to be an effective therapy for AMD. However, it does not lead to any improvement in the mean visual acuity.
The PIER (Phase IIIb, multicenter, randomized, double-masked, sham Injection-controlled study of the Efficacy and safety of Ranibizumab in subjects with subfoveal CNV with or without classic CNV secondary to age-related macular degeneration) study demonstrated that ranibizumab administered monthly for three months and then quarterly provided visual acuity benefits to patients with neovascular age related macular degeneration and was well tolerated. However, the observations from the MARINA and ANCHOR trials suggest that the PIER regimen of dosing every three months after three monthly doses provides less benefit in terms of visual acuity on average than continued monthly dosing. Monthly dosing may be necessary in some patients to achieve maximal treatment benefit from ranibizumab. Open Access 8 after 12 weeks of monthly or quarterly fixed dosing maintained clinically and statistically significant improvements in vision and retinal thickness until at least week 52 in patients with neovascular AMD, with a low frequency of reinjection.
VEGF Trap-Eye was generally well tolerated, with a safety profile similar to that reported with other intravitreally administered anti-VEGF agents.
The LEVEL (Evaluation of Efficacy and Safety in Maintaining Visual Acuity with Sequential Treatment of Neovascular age related macular degeneration) study assessed the efficacy of pegaptanib as maintenance therapy in AMD patients who experienced a clinical improvement in disease following an induction phase. The induction maintenance using nonselective, followed by selective VEGF inhibitors should be considered for the treatment of AMD. Such an approach has special relevance for patients with cardiovascular co morbidities who require anti-VEGF drugs to manage their AMD.
The VISION (VEGF Inhibition Study In Ocular Neovascularization) study demonstrated that in the group given pegaptanib at 0.3 mg, 70% of patients lost fewer than 15 letters of visual acuity, as compared with 55% among the controls (P < 0.001).
Conclusion
The knowledge of the molecular physiopathology of the CNV [31] prompted the treatment of different subtypes of its neovascular form. Several studies, some mentioned above, contributed for backing up the use of these agents worldwide, even though some studies are still on the way and others are to come. But the future promises better results, and the combination of treatments with other drugs and also old treatments such as laser and PDT and others are still applied.
Pharmacology gives us a broad spectrum of options, and together with other related specialties, to date nanotechnology [25] , gives us a better appreciation of the future. Some patients are prone to better results rather than other patients, and that may be corrected with different drugs switched after a good clinical evaluation, added with Octs and FA, as well as other diagnosing tools, such as Oct angiography.
We need more studies to compare, especially with the new OctA tool, and that will help us in the follow up of these patients and management of new patients in order to avoid the growth of the CNV.
Despite recurrent rates could be high and switching medications may be necessary for the sake of the patient's vision, that decision should be taken without delay, to avoid growth of the choroidal neovascular membrane ant its recurrence with devastating effects specially if located on the foveal area. We showed a case that needed retreatment with a new drug, switched to another medication able to perform better.
